Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ –
Highlights from Avanafil Development Program Include:
- Early onset of action observed in placebo-controlled trials
- Comparative in-vitro selectivity of avanafil, sildenafil, vardenafil and tadalafil
- Safety and efficacy in post-prostatectomy population
VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the Sexual Medicine Society of North America (SMSNA) on November 12, 2011 in Las Vegas, NV. The SMSNA is the largest gathering of medical professionals specializing in sexual dysfunction and treatment in North America.
The specific abstracts to be presented on November 12, 2011 include:
A moderated poster presentation by Wayne Hellstrom, MD, Professor of Urology and Chief of Andrology (male infertility and sexual dysfunction) at Tulane University School of Medicine, entitled:
Onset of Action and Time to Efficacy of Avanafil, a Novel, Rapid-Onset PDE5 Inhibitor in Men with Mild to Severe Erectile Dysfunction: Data From Phase 2 and Phase 3 Clinical Trials
Dr. Hellstrom will report that in the largest, randomized, phase 3 study of avanafil (TA-301), 67% of the patients who attempted intercourse within 15 minutes of dosing were successful.
A moderated poster presentation by Run Wang, MD, Associate Professor of Surgery in the Division of Urology and holder of the Cecil M. Crigler, MD Chair in Urology at the University of Texas Health Science Center in Houston, entitled:
Avanafil, a Highly Selective Phosphodiesterase Type 5 Inhibitor for the Treatment of Erectile Dysfunction: Selectivity for Eleven PDE Isozymes, in Comparison With Sildenafil, Tadalafil and Vardenafil
Dr. Wang will share his in-vitro analysis of avanafil selectivity for eleven PDE isozymes, in comparison with sildenafil, tadalafil and vardenafil. Dr. Wang concludes that, in-vitro, avanafil was the most selective PDE5i for all the eleven PDE isozymes.
Lastly, John Mulhall, MD, Director of the Male Sexual and Reproductive Medicine Program at the Memorial Sloan Kettering Cancer Center in New York, will present a poster entitled:
A Phase III, Placebo-Controlled Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Nerve-Sparing Radical Prostatectomy
In his presentation, Dr. Mulhall will summarize the safety and efficacy results of the phase 3, randomized study of avanafil for the treatment of erectile dysfunction in men following bilateral, nerve-sparing radical prostatectomy. In this study, radical prostatectomy patients treated with avanafil had significant improvement in erectile function as compared to the placebo-treated group.
Avanafil is an investigational oral drug being developed for the treatment of erectile dysfunction. Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead investigational product in clinical development, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010. We resubmitted the Qnexa NDA in October 2011, with an FDA action date of April 17, 2012. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “intend,” “likely,” “may,” “plan,” “potential,” predict,” “opportunity” and “should,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >=30 kg/m2), or overweight patients (BMI >=27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA’s interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA’s interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA’s response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner’s ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA’s CRL or CHMP’s 120-day questions, the FDA’s requests stemming from the end-of-review meeting or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP’s safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: -------- Investor VIVUS, Inc. Relations: The Trout Group Timothy E. Morris Brian Korb Chief Financial Officer email@example.com 650-934-5200 646-378-2923
SOURCE VIVUS, Inc.